In synovial sarcoma, where SS18-SSX is aberrantly expressed, it is hypothesized that EZH2 overactivity, either from loss of SWI/SNF-mediated EZH2 inhibition or by direct recruitment of EZH2 to polycomb targets, leads to tumorigenesis. The gene discussed is EZH2; the disease is synovial sarcoma.